$1.27
0.064.96%
Pre-Market: Jun 28, 5:54 PM EDT
15 minutes delayed
Inhibikase Therapeutics
IKTNASDAQ
Inhibikase Therapeutics (NASDAQ:IKT) Stock, Analyst Ratings, Price Targets, Predictions
Inhibikase Therapeutics Inc has a consensus price target of $11.5, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 21, 2024, March 7, 2024, and March 5, 2024. With an average price target of $25.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 2021.21% upside for Inhibikase Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Inhibikase Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/21/2024 | Buy Now | 1800.83% | HC Wainwright & Co. | Edward White | $27 → $23 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 2131.4% | HC Wainwright & Co. | Edward White | → $27 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 2131.4% | HC Wainwright & Co. | Edward White | $27 → $27 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 2131.4% | HC Wainwright & Co. | Edward White | → $27 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 2131.4% | HC Wainwright & Co. | Edward White | $5 → $27 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | 313.22% | HC Wainwright & Co. | Edward White | → $30 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | 313.22% | HC Wainwright & Co. | Edward White | → $30 | Initiates | → Buy | Get Alert |
| 11/16/2022 | Buy Now | — | JonesTrading | Soumit Roy | — | Downgrade | Buy → Hold | Get Alert |
| 07/15/2021 | Buy Now | 891.74% | JonesTrading | Soumit Roy | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Inhibikase Therapeutics (IKT) stock?
The latest price target for Inhibikase Therapeutics (NASDAQ:IKT) was reported by HC Wainwright & Co. on May 21, 2024. The analyst firm set a price target for $23.00 expecting IKT to rise to within 12 months (a possible 1800.83% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inhibikase Therapeutics (IKT)?
The latest analyst rating for Inhibikase Therapeutics (NASDAQ:IKT) was provided by HC Wainwright & Co., and Inhibikase Therapeutics maintained their buy rating.
When was the last upgrade for Inhibikase Therapeutics (IKT)?
There is no last upgrade for Inhibikase Therapeutics
When was the last downgrade for Inhibikase Therapeutics (IKT)?
The last downgrade for Inhibikase Therapeutics Inc happened on November 16, 2022 when JonesTrading changed their price target from N/A to N/A for Inhibikase Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Inhibikase Therapeutics (IKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibikase Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibikase Therapeutics was filed on May 21, 2024 so you should expect the next rating to be made available sometime around May 21, 2025.
Is the Analyst Rating Inhibikase Therapeutics (IKT) correct?
While ratings are subjective and will change, the latest Inhibikase Therapeutics (IKT) rating was a maintained with a price target of $27.00 to $23.00. The current price Inhibikase Therapeutics (IKT) is trading at is $1.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.